1086382-60-6Relevant articles and documents
Dihydroisoquinoline compound
-
Paragraph 0479-0484; 0491-0496, (2020/07/24)
The invention provides a dihydroisoquinoline compound or a pharmaceutically acceptable salt, ester, isomer, solvate, hydrate, prodrug or isotope marker thereof. The compound has a structure shown as ageneral formula I. The compound has extremely strong activity of inhibiting hepatitis B surface antigen, also has extremely strong activity of inhibiting hepatitis B DNA, has relatively high bioavailability, can play a drug effect at a relatively low dosage, and reduces the potential toxicity of the compound.
TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS
-
Page/Page column 96, (2010/01/12)
A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and methods of treating conditions associated with the activity of